Latest Posts
About This Stock
More About This Stock
Read
Read
Key FDA Events In June Investors Need To Watch Out For
Article By:
Zacks Investment Research
Sunday, June 3, 2018 12:49 PM EDT
It has been a busy year for the FDA so far with the agency approving 14 drugs. The approval of these drugs should boost their respective companies’ top line as a few of them are struggling with decline in sales of legacy drugs.
Deutsche Raises Valeant Price Target On Extended Xifaxan Exclusivity
Article By:
The Fly
Monday, April 30, 2018 3:42 PM EDT
The stay in the Xifaxan litigation between Valeant Pharmaceuticals and Teva was recently extended to July 30, 2018, from April 30, 2018, and may be extended further, Deutsche Bank analyst Gregg Gilbert tells investors in an intraday research note.